OKUR (OnKure Therapeutics) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)


OKUR OnKure Therapeutics Inc OKUR
14 GF Score
Price $4.39
! 2 Warning Signs
View Full Analysis

What is OnKure Therapeutics LT-Debt-to-Total-Asset?

OnKure Therapeutics OKUR -5.39% 14 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates OKUR with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. OnKure Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

OnKure Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.00) to Mar. 2026 (0.00). It may suggest that OnKure Therapeutics is progressively becoming less dependent on debt to grow their business.

OnKure Therapeutics  (NAS:OKUR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

OnKure Therapeutics LT-Debt-to-Total-Asset Related Terms

OnKure Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for OnKure Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OnKure Therapeutics LT-Debt-to-Total-Asset Chart

OnKure Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.03 0.01 0.01 0.00

OnKure Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OKUR
14GF Score
OnKure Therapeutics Inc OKUR
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OnKure Therapeutics LT-Debt-to-Total-Asset Calculation

OnKure Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0/62.117
=

OnKure Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0/198.694
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
OnKure Therapeutics (OKUR) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OnKure Therapeutics and its competitors.
Is OnKure Therapeutics' LT-Debt-to-Total-Asset too high?
OnKure Therapeutics' current LT-Debt-to-Total-Asset is 0.00. Overall, OnKure Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does OnKure Therapeutics' LT-Debt-to-Total-Asset compare to ANTX and PLX?
OnKure Therapeutics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OnKure Therapeutics and its competitors. OnKure Therapeutics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OnKure Therapeutics stock overvalued right now?
OnKure Therapeutics (OKUR) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. OnKure Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For OnKure Therapeutics (OKUR), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OnKure Therapeutics Business Description

Address 6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3K?. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
14GF Score

Get the complete analysis for OKUR

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.39
Price